Velphoro is a prescription medication that comes in the form of chewable tablets. It contains sucroferric oxyhydroxide, a powerful phosphate binder, which plays a significant role in managing phosphate levels in patients with chronic kidney disease (CKD).
This article aims to provide a comprehensive overview of Velphoro 500 mg chewable tablets, including its mechanism of action, medical uses, recommended dosage, side effects, and important considerations for patients.
What is Velphoro 500 mg chewable tablets?
Velphoro 500 mg chewable tablets are designed to help control serum phosphorus levels in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. Each tablet contains 500 mg of sucroferric oxyhydroxide, which is equivalent to 500 mg of elemental iron.
These chewable tablets are suitable for adult patients and for pediatric patients aged 2 years and older. It is important to note that Velphoro is taken with meals to effectively reduce dietary phosphate absorption.
The medication is made to be palatable and easy to chew, allowing for convenient intake, especially for those who may have difficulty swallowing pills. This feature makes it a preferred choice among patients requiring phosphate control.
How does Velphoro work?
Velphoro works by binding dietary phosphate in the gastrointestinal tract. This action prevents the absorption of phosphate into the bloodstream, thereby lowering serum phosphorus levels. It is crucial for patients with CKD, as elevated phosphate levels can lead to various complications, including cardiovascular issues and bone disorders.
The active ingredient, sucroferric oxyhydroxide, is an iron-based compound that functions effectively as a phosphate binder. By reducing the absorption of phosphate, it helps maintain the patient’s phosphorus levels within a safe range.
Moreover, the iron component aids in managing anemia, a common issue in patients with CKD. Therefore, Velphoro not only addresses phosphate control but also contributes to improving overall iron levels in the body.
What are the medical uses of Velphoro?
Velphoro is primarily used to manage serum phosphorus levels in patients with chronic kidney disease (CKD) who are on dialysis. High phosphorus levels can lead to serious health complications, making effective management essential.
Additionally, Velphoro is indicated for pediatric patients, starting from the age of 2, who experience high phosphate levels due to CKD. This makes it a versatile option for different patient demographics.
Other potential uses include managing iron deficiency in patients where phosphate binders are necessary. The medication’s dual action can be beneficial in addressing multiple aspects of CKD management.
What dosage of Velphoro is recommended?
The recommended starting dosage of Velphoro for adults is typically 1,500 mg of iron daily. This translates to three chewable tablets taken daily, with adjustments made based on serum phosphorus levels.
Patients are advised to have their phosphorus levels monitored every 2 to 4 weeks, allowing healthcare providers to make necessary dosage adjustments. The maximum recommended dose is 3,000 mg of iron per day.
For pediatric patients aged 2 years and older, the dosage may vary based on individual needs and should be determined by a healthcare professional. It is vital to adhere to the prescribed dosage to ensure effective phosphate management.
What are the side effects of Velphoro?
As with any medication, Velphoro may cause side effects. Common side effects include diarrhea and discolored feces, which are often reported by users. While these symptoms can be bothersome, they tend to diminish over time as the body adjusts to the medication.
Other less common side effects may include abdominal pain and nausea. It is essential for patients to communicate any adverse reactions to their healthcare provider to evaluate the need for potential adjustments in therapy.
Despite these side effects, the benefits of Velphoro in managing phosphate levels generally outweigh the risks, especially considering the serious complications associated with untreated hyperphosphatemia.
How does Velphoro compare to sevelamer?
Velphoro and sevelamer are both phosphate binders used to control serum phosphorus levels in patients with CKD. However, they differ in their composition and mechanisms of action.
- Velphoro: Contains sucroferric oxyhydroxide, an iron-based binder that also contributes to iron levels in the body.
- Sevelamer: A non-calcium, non-metal phosphate binder that does not contain iron and is less effective in improving anemia.
While both medications are effective, the choice between Velphoro and sevelamer may depend on the individual patient’s health status, particularly regarding iron levels and tolerance to side effects.
What should patients know before taking Velphoro?
Before initiating treatment with Velphoro, patients should be aware of certain contraindications. Those with hypersensitivity to sucroferric oxyhydroxide or related compounds should avoid this medication.
Patients with disorders related to iron accumulation should also consult their healthcare provider before starting Velphoro, as the iron component may exacerbate these conditions.
Furthermore, it is crucial for patients to inform their healthcare provider of all medications they are currently taking, as Velphoro may interact with certain drugs, including levothyroxine. Taking Velphoro with meals can enhance its efficacy, so timing and adherence to the prescribed regimen are essential.
Related questions about Velphoro
What is Velphoro 500 mg used for?
Velphoro 500 mg is used primarily for managing elevated serum phosphorus levels in patients with chronic kidney disease (CKD), particularly those undergoing dialysis. This medication helps prevent complications associated with high phosphorus levels, such as cardiovascular disease and bone disorders.
In addition to its primary use, Velphoro may assist in improving iron levels in patients suffering from anemia related to CKD. This multifaceted approach provides comprehensive management for patients facing these health challenges.
Is Velphoro the same as sevelamer?
No, Velphoro and sevelamer are not the same. Velphoro contains sucroferric oxyhydroxide, an iron-based phosphate binder, while sevelamer is a non-calcium and non-metal binder. They both serve the same purpose of managing phosphate levels, but their compositions and some mechanisms differ.
The choice between these two medications depends on individual patient needs and health conditions. Consulting a healthcare provider can help determine which option is best suited.
What are the ingredients in Velphoro?
Velphoro contains sucroferric oxyhydroxide as its active ingredient. Each chewable tablet delivers 500 mg of this compound, which is effective in binding phosphate in the gastrointestinal tract.
In addition to the active ingredient, Velphoro may contain various excipients to ensure the tablet’s stability, texture, and flavor. These ingredients work together to provide an effective and palatable medication for patients.
What is the use of sucroferric oxyhydroxide chewable tablets?
Sucroferric oxyhydroxide chewable tablets, marketed as Velphoro, are primarily used to manage serum phosphorus levels in patients with chronic kidney disease (CKD). They are crucial for preventing complications associated with elevated phosphate levels.
Moreover, these chewable tablets help improve iron levels in patients suffering from CKD-related anemia, providing a dual benefit to users and improving their overall health and well-being.